Adam C. LaRock

I'll research this attorney before drafting.

Adam C. LaRock — Patent Litigation Practice Summary

Specialty / focus. LaRock's practice is centered on pharmaceutical and biotechnology patent litigation, with particular depth in Hatch-Waxman ANDA cases and BPCIA/biosimilar disputes. Sterne Kessler's bio describes him as handling innovator, generic, and biosimilar clients across new chemical entities, enantiomers, prodrugs, salt/solid-state forms, formulations, combinations, and methods of treatment, as well as brand-vs-brand pharma litigation. His technical background is chemistry (B.S., Clarkson University), and his docket history includes non-pharma work as well — Federal Circuit appeals from IPRs on near-field communication devices, district court litigation over stray-voltage-detection apparatus patents, and diagnostic gene-testing patents.

Side preference. The tracked docket data shows two appearances, both on the defendant side (one as lead counsel), and no plaintiff-side appearances. That is a partial picture: his publicly described practice runs both sides of the "v." He has represented generic/ANDA filers, brand/innovator companies, and universities, and court filings show him appearing as counsel for plaintiffs — for example, American Regent, Inc. in In re Selenious Acid Litigation (D.N.J. 2:24-cv-07791) and Breckenridge Pharmaceutical in Breckenridge Pharm., Inc. v. Hetero USA, Inc. (D. Del. C.A. No. 24-571). Patexia's 2025 ANDA Litigation Intelligence Report ranked him in the top ten both overall and for plaintiff-side activity and performance. He is not an NPE/PAE-side prosecutor; his clients are operating companies and life-sciences patent holders.

Firm context. He is a director in Sterne Kessler's Trial & Appellate Practice Group, elected to director effective January 1, 2018 (he joined the firm as an associate). Before Sterne Kessler he was an associate at Fitzpatrick, Cella, Harper & Scinto in New York (appearing in that capacity as late as 2014 in the Gilead v. Teva matter). No in-house role is indicated.

Notable matters and PTAB/IPR experience. His firm bio credits him with leading teams in more than thirty-five patent cases, and PTAB records confirm regular IPR appearances in pharma matters — including backup counsel in IPR2017-00807 (Argentum Pharmaceuticals, Dymista-related '620 patent), IPR2019-00207 (Amneal v. Almirall, U.S. Pat. 9,517,219), IPR2021-01204 (Revance Therapeutics v. Medy-Tox), and IPR2022-00055 (Unified Patents). On the tracked matters: the docket lists him as counsel for the defendant in Unified Patents, LLC v. Breckenridge Pharmaceutical Inc.; I could not independently verify the details of that specific matter through public searches, so its subject matter should not be assumed. He is a contributing author of Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio (3d ed., ABA 2022).

Bar / education. Admitted in New York (2010), the District of Columbia (2015), the U.S. Court of Appeals for the Federal Circuit (2015), and the USPTO (Reg. No. 64,681); J.D., University of New Hampshire Franklin Pierce School of Law; B.S. in Chemistry, Clarkson University.

Note on sourcing: a stale USPTO-derived directory entry lists the same registration number under Fitzpatrick Cella, reflecting his prior employer rather than a separate attorney; no conflicting practitioner of the same name was identified. No public record of the outcome of the Unified Patents v. Breckenridge matter was located.